Clinical implications of epithelial cell plasticity in cancer progression

Cancer Letters

Volumn 366, Issue 1, 2015, Pages 1-10

  Aparicio, Luis A ^a   Blanco, Moisés ^b   Castosa, Raquel ^b   Concha, Ángel ^a   Valladares, Manuel ^a   Calvo, Lourdes ^a   Figueroa, Angélica ^b  

^a UNIVERSITY OF A CORUÑA   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Cancer stem cells; Circulating tumour cells; Drug resistance; Epithelial plasticity; Medical perspective

Indexed keywords

HOMEODOMAIN PROTEIN; NUCLEAR PROTEIN; PRRX1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

CANCER STEM CELL; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TUMOR EMBOLISM;

DISEASE PROGRESSION; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; TWIST TRANSCRIPTION FACTOR;

EID: 84937526927     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.06.007     Document Type: Review

References (119)

1. Lim J., Thiery J.P. Epithelial-mesenchymal transitions: insights from development. Development 2012, 139:3471-3486.
2. Nieto M.A., Cano A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin. Cancer Biol 2012, 22:361-368.
3. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
4. Trelstad R.L., Hay E.D., Revel J.D. Cell contact during early morphogenesis in the chick embryo. Dev. Biol 1967, 16:78-106.
5. Hay E.D. Organization and Fine Structure of Epithelium and Mesenchyme in the Developing Chickembryo 1968, Baltimore, MD.
6. Hay E.D. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev. Dyn 2005, 233:706-720.
7. Nieto M.A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 2013, 342:1234850.
8. Vleminckx K., Vakaet L., Mareel M., Fiers W., van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991, 66:107-119.
9. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894-907.
10. Abella V., Valladares M., Rodriguez T., Haz M., Blanco M., Tarrío N., et al. miR-203 regulates cell proliferation through its influence on Hakai expression. PLoS ONE 2012, 7:e52568.
11. Aparicio L.A., Abella V., Valladares M., Figueroa A. Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition. Cell. Mol. Life Sci 2013, 70:4463-4477.
12. Aparicio L.A., Valladares M., Blanco M., Alonso G., Figueroa A. Biological influence of Hakai in cancer: a 10-year review. Cancer Metastasis Rev 2012, 31:375-386.
13. Rodríguez-Rigueiro T., Valladares-Ayerbes M., Haz-Conde M., Aparicio L.A., Figueroa A. Hakai reduces cell-substratum adhesion and increases epithelial cell invasion. BMC Cancer 2011, 11:474.
14. Dupre-Crochet S., Figueroa A., Hogan C., Ferber E.C., Bialucha C.U., Adams J., et al. Casein kinase 1 is a novel negative regulator of E-cadherin-based cell-cell contacts. Mol. Cell. Biol 2007, 27:3804-3816.
15. Fujita Y., Krause G., Scheffner M., Zechner D., Leddy H., Behrens J., et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat. Cell Biol 2002, 4:222-231.
16. Batlle E., Henderson J.T., Beghtel H., van den Born M.M., Sancho E., Huls G., et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002, 111:251-263.
17. Batlle E., Bacani J., Begthel H., Jonkheer S., Jonkeer S., Gregorieff A., et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005, 435:1126-1130.
18. Miura K., Nam J.M., Kojima C., Mochizuki N., Sabe H. EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts. Mol. Biol. Cell 2009, 20:1949-1959.
19. Watanabe T., Sato Y., Saito D., Tadokoro R., Takahashi Y. EphrinB2 coordinates the formation of a morphological boundary and cell epithelialization during somite segmentation. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7467-7472.
20. Pasquale E.B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 2010, 10:165-180.
21. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr. Opin. Cell Biol 1993, 5:806-811.
22. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
23. Entenberg D., Kedrin D., Wyckoff J., Sahai E., Condeelis J., Segall J.E. Imaging tumor cell movement in vivo. Curr. Protoc. Cell Biol 2013, 58:19.7.1-19.7.19.
24. Valladares-Ayerbes M., Reboredo M., Medina-Villaamil V., Iglesias-Díaz P., Lorenzo-Patiño M.J., Haz M., et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J. Transl. Med 2012, 10:186.
25. Valladares-Ayerbes M., Blanco-Calvo M., Reboredo M., Lorenzo-Patiño M.J., Iglesias-Díaz P., Haz M., et al. Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer. Int. J. Mol. Sci 2012, 13:4367-4387.
26. Bednarz-Knoll N., Alix-Panabières C., Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 2012, 31:673-687.
27. Marjanovic N.D., Weinberg R.A., Chaffer C.L. Cell plasticity and heterogeneity in cancer. Clin. Chem 2013, 59:168-179.
28. Li L.F., Wei Z.J., Sun H., Jiang B. Abnormal β-catenin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis. World J. Gastroenterol 2014, 20:12313-12321.
29. Zeng R., Duan L., Kong Y.K., Wu X.L., Wang Y., Xin G., et al. Prognostic significance of beta-catenin expression in patients with esophageal carcinoma: a meta-analysis. Asian Pac. J. Cancer Prev 2014, 15:6103-6108.
30. Chen Z., He X., Jia M., Liu Y., Qu D., Wu D., et al. β-catenin overexpression in the nucleus predicts progress disease and unfavourable survival in colorectal cancer: a meta-analysis. PLoS ONE 2013, 8:e63854.
31. Mei X.D., Su H., Song J., Dong L. Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a meta-analysis. Biosci. Trends 2013, 7:42-49.
32. Zhang P., Hu P., Shen H., Yu J., Liu Q., Du J. Prognostic role of Twist or Snail in various carcinomas: a systematic review and meta-analysis. Eur. J. Clin. Invest 2014, 44:1072-1094.
33. Yan B., Zhang W., Jiang L.Y., Qin W.X., Wang X. Reduced E-Cadherin expression is a prognostic biomarker of non-small cell lung cancer: a meta-analysis based on 2395 subjects. Int. J. Clin. Exp. Med 2014, 7:4352-4356.
34. Yang Y.L., Chen M.W., Xian L. Prognostic and clinicopathological significance of downregulated E-cadherin expression in patients with non-small cell lung cancer (NSCLC): a meta-analysis. PLoS ONE 2014, 9:e99763.
35. He X., Chen Z., Jia M., Zhao X. Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis. PLoS ONE 2013, 8:e70858.
36. Xu X.L., Ling Z.Q., Chen S.Z., Li B., Ji W.H., Mao W.M. The impact of E-cadherin expression on the prognosis of esophageal cancer: a meta-analysis. Dis. Esophagus 2014, 27:79-86.
37. Xing X., Tang Y.B., Yuan G., Wang Y., Wang J., Yang Y., et al. The prognostic value of E-cadherin in gastric cancer: a meta-analysis. Int. J. Cancer 2013, 132:2589-2596.
38. Peng H.L., He L., Zhao X. Association of reduced immunohistochemical expression of E-cadherin with a poor ovarian cancer prognosis - results of a meta-analysis. Asian Pac. J. Cancer Prev 2012, 13:2003-2007.
39. Zhao Z., Ge J., Sun Y., Tian L., Lu J., Liu M., et al. Is E-cadherin immunoexpression a prognostic factor for head and neck squamous cell carcinoma (HNSCC)? A systematic review and meta-analysis. Oral Oncol 2012, 48:761-767.
40. Jamieson N.B., Carter C.R., McKay C.J., Oien K.A. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin. Cancer Res 2011, 17:3316-3331.
41. Gould Rothberg B.E., Bracken M.B. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res. Treat 2006, 100:139-148.
42. Shao Y., Geng Y., Gu W., Huang J., Pei H., Jiang J. Prognostic role of tissue and circulating microRNA-200c in malignant tumors: a systematic review and meta-analysis. Cell. Physiol. Biochem 2015, 35:1188-1200.
43. Gupta P.B., Mani S., Yang J., Hartwell K., Weinberg R.A. The evolving portrait of cancer metastasis. Cold Spring Harb. Symp. Quant. Biol 2005, 70:291-297.
44. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
45. Bitting R.L., Schaeffer D., Somarelli J.A., Garcia-Blanco M.A., Armstrong A.J. The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev 2014, 33:441-468.
46. Ledford H. Cancer theory faces doubts. Nature 2011, 472:273.
47. Greco F.A., Hainsworth J.D. Introduction: unknown primary cancer. Semin. Oncol 2009, 36:6-7.
48. Ocaña O.H., Córcoles R., Fabra A., Moreno-Bueno G., Acloque H., Vega S., et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012, 22:709-724.
49. Tsai J.H., Donaher J.L., Murphy D.A., Chau S., Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012, 22:725-736.
50. Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361.
51. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
52. Kang Y., Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004, 118:277-279.
53. Yu M., Bardia A., Wittner B.S., Stott S.L., Smas M.E., Ting D.T., et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339:580-584.
54. Gradilone A., Raimondi C., Nicolazzo C., Petracca A., Gandini O., Vincenzi B., et al. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J. Cell. Mol. Med 2011, 15:1066-1070.
55. Kaiser J. Medicine. Cancer's circulation problem. Science 2010, 327:1072-1074.
56. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
57. Pattabiraman D.R., Weinberg R.A. Tackling the cancer stem cells - what challenges do they pose?. Nat. Rev. Drug Discov 2014, 13:497-512.
58. Merlos-Suárez A., Barriga F.M., Jung P., Iglesias M., Céspedes M.V., Rossell D., et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011, 8:511-524.
59. Santisteban M., Reiman J.M., Asiedu M.K., Behrens M.D., Nassar A., Kalli K.R., et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009, 69:2887-2895.
60. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.S., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69:4116-4124.
61. Brabletz T., Hlubek F., Spaderna S., Schmalhofer O., Hiendlmeyer E., Jung A., et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005, 179:56-65.
62. Niu R.F., Zhang L., Xi G.M., Wei X.Y., Yang Y., Shi Y.R., et al. Up-regulation of Twist induces angiogenesis and correlates with metastasis in hepatocellular carcinoma. J. Exp. Clin. Cancer Res 2007, 26:385-394.
63. Morel A.P., Lièvre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3:e2888.
64. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009, 69:2400-2407.
65. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9:582-589.
66. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol 2009, 11:1487-1495.
67. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:7950-7955.
68. Guo W., Keckesova Z., Donaher J.L., Shibue T., Tischler V., Reinhardt F., et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012, 148:1015-1028.
69. Celià-Terrassa T., Meca-Cortés O., Mateo F., de Paz A.M., Rubio N., Arnal-Estapé A., et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J. Clin. Invest 2012, 122:1849-1868.
70. Scheel C., Weinberg R.A. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol 2012, 22:396-403.
71. Zhao C., Blum J., Chen A., Kwon H.Y., Jung S.H., Cook J.M., et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12:528-541.
72. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clin. Cancer Res 2010, 16:3153-3162.
73. Wend P., Holland J.D., Ziebold U., Birchmeier W. Wnt signaling in stem and cancer stem cells. Semin. Cell Dev. Biol 2010, 21:855-863.
74. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
75. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat. Rev. Cancer 2006, 6:449-458.
76. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol 2009, 20:1223-1229.
77. Aktas B., Tewes M., Fehm T., Hauch S., Kimmig R., Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009, 11:R46.
78. Kallergi G., Papadaki M.A., Politaki E., Mavroudis D., Georgoulias V., Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 2011, 13:R59.
79. Min A.L., Choi J.Y., Woo H.Y., Kim J.D., Kwon J.H., Bae S.H., et al. High expression of Snail mRNA in blood from hepatocellular carcinoma patients with extra-hepatic metastasis. Clin. Exp. Metastasis 2009, 26:759-767.
80. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 2008, 8:329-340.
81. Patriarca C., Macchi R.M., Marschner A.K., Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat. Rev 2012, 38:68-75.
82. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol 2008, 26:3213-3221.
83. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res 2008, 14:6302-6309.
84. Barrière G., Tartary M., Rigaud M. Epithelial mesenchymal transition: a new insight into the detection of circulating tumor cells. ISRN Oncol 2012, 2012:382010.
85. Millner L.M., Linder M.W., Valdes R. Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann. Clin. Lab. Sci 2013, 43:295-304.
86. Grover P.K., Cummins A.G., Price T.J., Roberts-Thomson I.C., Hardingham J.E. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann. Oncol 2014, 25:1506-1516.
87. Mego M., Mani S.A., Lee B.N., Li C., Evans K.W., Cohen E.N., et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int. J. Cancer 2012, 130:808-816.
88. Giordano A., Gao H., Anfossi S., Cohen E., Mego M., Lee B.N., et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol. Cancer Ther 2012, 11:2526-2534.
89. Mego M., Gao H., Lee B.N., Cohen E.N., Tin S., Giordano A., et al. Prognostic value of EMT-circulating tumor cells in metastatic breast cancer patients undergoing high-dose chemotherapy with autologous hematopoietic stem cell transplantation. J. Cancer 2012, 3:369-380.
90. Watson M.A., Ylagan L.R., Trinkaus K.M., Gillanders W.E., Naughton M.J., Weilbaecher K.N., et al. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin. Cancer Res 2007, 13:5001-5009.
91. Antolín S., Calvo L., Blanco-Calvo M., Santiago M.P., Lorenzo-Patiño M.J., Haz-Conde M., et al. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer 2015, 15:297.
92. Chaffer C.L., Brennan J.P., Slavin J.L., Blick T., Thompson E.W., Williams E.D. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006, 66:11271-11278.
93. Kolonin M.G., Evans K.W., Mani S.A., Gomer R.H. Alternative origins of stroma in normal organs and disease. Stem Cell Res 2012, 8:312-323.
94. Noman M.Z., Messai Y., Carré T., Akalay I., Méron M., Janji B., et al. Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit. Rev. Immunol 2011, 31:357-377.
95. Kudo-Saito C., Shirako H., Takeuchi T., Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009, 15:195-206.
96. Nieto M.A. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu. Rev. Cell Dev. Biol 2011, 27:347-376.
97. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009, 69:5820-5828.
98. Nantajit D., Lin D., Li J.J. The network of epithelial-mesenchymal transition: potential new targets for tumor resistance. J. Cancer Res. Clin. Oncol 2014, 10.1007/s00432-014-1840-y.
99. Buck E., Eyzaguirre A., Barr S., Thompson S., Sennello R., Young D., et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol. Cancer Ther 2007, 6:532-541.
100. Frederick B.A., Helfrich B.A., Coldren C.D., Zheng D., Chan D., Bunn P.A., et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol. Cancer Ther 2007, 6:1683-1691.
101. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
102. Cheng G.Z., Chan J., Wang Q., Zhang W., Sun C.D., Wang L.H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007, 67:1979-1987.
103. Hsu D.S., Lan H.Y., Huang C.H., Tai S.K., Chang S.Y., Tsai T.L., et al. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin. Cancer Res 2010, 16:4561-4571.
104. Latifi A., Abubaker K., Castrechini N., Ward A.C., Liongue C., Dobill F., et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J. Cell. Biochem 2011, 112:2850-2864.
105. Shintani Y., Okimura A., Sato K., Nakagiri T., Kadota Y., Inoue M., et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann. Thorac. Surg 2011, 92:1794-1804. discussion 1804.
106. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005, 65:9455-9462.
107. Yauch R.L., Januario T., Eberhard D.A., Cavet G., Zhu W., Fu L., et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res 2005, 11:8686-8698.
108. Xie M., Zhang L., He C.S., Xu F., Liu J.L., Hu Z.H., et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J. Cell. Biochem 2012, 113:1501-1513.
109. Oliveras-Ferraros C., Corominas-Faja B., Cufí S., Vazquez-Martin A., Martin-Castillo B., Iglesias J.M., et al. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle 2012, 11:4020-4032.
110. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst 2008, 100:672-679.
111. Ou S.H., Bazhenova L., Camidge D.R., Solomon B.J., Herman J., Kain T., et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J. Thorac. Oncol 2010, 5:2044-2046.
112. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med 2009, 361:947-957.
113. Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov 2008, 7:504-516.
114. Cañadas I., Rojo F., Taus Á., Arpí O., Arumí-Uría M., Pijuan L., et al. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin. Cancer Res 2014, 20:938-950.
115. Xiong X., Arvizo R.R., Saha S., Robertson D.J., McMeekin S., Bhattacharya R., et al. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget 2014, 5:6453-6465.
116. Yang D., Sun Y., Hu L., Zheng H., Ji P., Pecot C.V., et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013, 23:186-199.
117. Hüsemann Y., Geigl J.B., Schubert F., Musiani P., Meyer M., Burghart E., et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
118. Garralda E., Paz K., López-Casas P.P., Jones S., Katz A., Kann L.M., et al. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clin. Cancer Res 2014, 20:2476-2484.
119. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., Garrido-Laguna I., De Oliveira E., Rubio-Viqueira B., et al. A pilot clinical study of treatment guided by personalized tumor grafts in patients with advanced cancer. Mol. Cancer Ther 2011, 10:1311-1316.